Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.

Samuel Rosner,Joshua E Reuss,Marianna Zahurak,Jiajia Zhang,Zhen Zeng,Janis Taube,Valsamo Anagnostou,Kellie N Smith,Joanne Riemer,Peter B Illei,Stephen R Broderick,David R Jones,Suzanne L Topalian,Drew M Pardoll,Julie R Brahmer,Jamie E Chaft,Patrick M Forde

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 12|浏览36

暂无评分

摘要

Five-year clinical outcomes for neoadjuvant nivolumab in resectable NSCLC compare favorably with historical outcomes. MPR and PD-L1 positivity trended toward improved RFS, though definitive conclusions are limited by cohort size.

查看译文

关键词

neoadjuvant nivolumab,non–small cell lung cancer,five-year

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要